FibroGen Inc. has announced the entry into a Third Amendment to its existing financing agreement with investment funds managed by Morgan Stanley Tactical Value. The amendment, dated July 14, 2025, involves a reduction in the minimum qualified cash balance that FibroGen is required to maintain in its U.S. deposit or securities accounts, lowering the amount from $22.5 million to $18.75 million. This amendment is part of an ongoing financing arrangement initially established on April 29, 2023, and managed by Wilmington Trust National Association as the administrative agent. The details of this amendment are documented in the full text filed as Exhibit 10.1 to the company's current report on Form 8-K.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. FibroGen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-095628), on July 14, 2025, and is solely responsible for the information contained therein.